Drug Trial Radar · NCT07581951
A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
886
Planned (sponsor's estimate)
Start
Jun 30, 2026
Primary completion
Jun 30, 2029
Study completion Dec 30, 2032
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of HSK31679 compared to placebo in patients with metabolic dysfunction-associated steatohepatitis (MASH) .
Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- NASH (Non-Alcoholic Steatohepatitis)
Interventions
HSK31679Drug
tablet
PlaceboDrug
Matching tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Resolution of Steatohepatitis Without Worsening of Fibrosis at Week 52.Time frame: Week 52
- Number of Participants With at Least an Improvement of Fibrosis ≥1 Stage Without Worsening of Steatohepatitis at Week 52.Time frame: Week 52
- Time to First Occurrence of Disease ProgressionTime frame: Up to 4.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.